UCSF Coronavirus Response: UCSF is partnering with public agencies to address the rapidly evolving outbreak and protect our communities. The UCSF COVID-19 Resources Website provides guidance and information for our patients, faculty, staff, trainees and learners.

Chukwuka Didigu, MD, PhD

Title(s)Clinical Fellow, Medicine
SchoolSchool of Medicine
Phone415-221-4810 ext. 2129
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Didigu C, Doms R. Gene therapy targeting HIV entry. Viruses. 2014 Mar 21; 6(3):1395-409. PMID: 24662607.
      View in: PubMed
    2. Petersen J, Drake MJ, Bruce EA, Riblett AM, Didigu CA, Wilen CB, Malani N, Male F, Lee FH, Bushman FD, Cherry S, Doms RW, Bates P, Briley K. The major cellular sterol regulatory pathway is required for Andes virus infection. PLoS Pathog. 2014 Feb; 10(2):e1003911. PMID: 24516383.
      View in: PubMed
    3. Didigu CA, Wilen CB, Wang J, Duong J, Secreto AJ, Danet-Desnoyers GA, Riley JL, Gregory PD, June CH, Holmes MC, Doms RW. Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. Blood. 2014 Jan 02; 123(1):61-9. PMID: 24162716.
      View in: PubMed
    4. Singer EM, Shin DB, Nattkemper LA, Benoit BM, Klein RS, Didigu CA, Loren AW, Dentchev T, Wysocka M, Yosipovitch G, Rook AH. IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus. J Invest Dermatol. 2013 Dec; 133(12):2783-2785. PMID: 23698099.
      View in: PubMed
    5. Wojcechowskyj JA, Didigu CA, Lee JY, Parrish NF, Sinha R, Hahn BH, Bushman FD, Jensen ST, Seeholzer SH, Doms RW. Quantitative phosphoproteomics reveals extensive cellular reprogramming during HIV-1 entry. Cell Host Microbe. 2013 May 15; 13(5):613-623. PMID: 23684312.
      View in: PubMed
    6. Parker ZF, Iyer SS, Wilen CB, Parrish NF, Chikere KC, Lee FH, Didigu CA, Berro R, Klasse PJ, Lee B, Moore JP, Shaw GM, Hahn BH, Doms RW. Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J Virol. 2013 Mar; 87(5):2401-11. PMID: 23269796.
      View in: PubMed
    7. Richardson MW, Jadlowsky J, Didigu CA, Doms RW, Riley JL. Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection. J Immunol. 2012 Oct 15; 189(8):3815-21. PMID: 22988032.
      View in: PubMed
    8. Zheng X, Xu C, Smith AO, Stratman AN, Zou Z, Kleaveland B, Yuan L, Didiku C, Sen A, Liu X, Skuli N, Zaslavsky A, Chen M, Cheng L, Davis GE, Kahn ML. Dynamic regulation of the cerebral cavernous malformation pathway controls vascular stability and growth. Dev Cell. 2012 Aug 14; 23(2):342-55. PMID: 22898778.
      View in: PubMed
    9. Didigu CA, Doms RW. Novel approaches to inhibit HIV entry. Viruses. 2012 Feb; 4(2):309-24. PMID: 22470838.
      View in: PubMed
    10. Tilton JC, Wilen CB, Didigu CA, Sinha R, Harrison JE, Agrawal-Gamse C, Henning EA, Bushman FD, Martin JN, Deeks SG, Doms RW. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J Virol. 2010 Oct; 84(20):10863-76. PMID: 20702642.
      View in: PubMed
    Chukwuka's Networks
    Derived automatically from this person's publications.
    People in Profiles who have published with this person.
    Similar People
    People who share similar concepts with this person.
    Same Department